<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Marrella, Veronica</dc:creator>
  <dc:creator>Poliani, Pietro L.</dc:creator>
  <dc:creator>Fontana, Elena</dc:creator>
  <dc:creator>Casati, Anna</dc:creator>
  <dc:creator>Maina, Virginia</dc:creator>
  <dc:creator>Cassani, Barbara</dc:creator>
  <dc:creator>Ficara, Francesca</dc:creator>
  <dc:creator>Cominelli, Manuela</dc:creator>
  <dc:creator>Schena, Francesca</dc:creator>
  <dc:creator>Paulis, Marianna</dc:creator>
  <dc:creator>Traggiai, Elisabetta</dc:creator>
  <dc:creator>Vezzoni, Paolo</dc:creator>
  <dc:creator>Grassi, Fabio</dc:creator>
  <dc:creator>Villa, Anna</dc:creator>
  <dc:description xmlns:ns0="xml" ns0:lang="en">&lt;jats:title&gt;Abstract&lt;/jats:title&gt;
               &lt;jats:p&gt;Omenn syndrome (OS) is an atypical primary immunodeficiency characterized by severe autoimmunity because of activated T cells infiltrating target organs. The impaired recombinase activity in OS severely affects expression of the pre-T-cell receptor complex in immature thymocytes, which is crucial for an efficient development of the thymic epithelial component. Anti-CD3ε monoclonal antibody (mAb) treatment in RAG2−/− mice was previously shown to mimic pre-TCR signaling promoting thymic expansion. Here we show the effect of anti-CD3ε mAb administration in the RAG2R229Q mouse model, which closely recapitulates human OS. These animals, in spite of the inability to induce the autoimmune regulator, displayed a significant amelioration in thymic epithelial compartment and an important reduction of peripheral T-cell activation and tissue infiltration. Furthermore, by injecting a high number of RAG2R229Q progenitors into RAG2−/− animals previously conditioned with anti-CD3ε mAb, we detected autoimmune regulator expression together with the absence of peripheral immunopathology. These observations indicate that improving epithelial thymic function might ameliorate the detrimental behavior of the cell-autonomous RAG defect. Our data provide important therapeutic proof of concept for future clinical applications of anti-CD3ε mAb treatment in severe combined immunodeficiency forms characterized by poor thymus function and autoimmunity.&lt;/jats:p&gt;</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/139653</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1182/blood-2012-01-406827</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0006-4971</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Blood. - American Society of Hematology. - 2012, vol. 120, no. 5, p. 1005-1014</dc:source>
  <dc:title xmlns:ns1="xml" ns1:lang="en">Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
